The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Immunovant Inc (NASDAQ: IMVT) was $14.70 for the day, up 1.66% from the previous closing price of $14.46. In other words, the price has increased by $1.66 from its previous closing price. On the day, 1.24 million shares were traded.
Ratios:
Our analysis of IMVT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.04 and its Current Ratio is at 6.04. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on March 03, 2025, initiated with a Hold rating and assigned the stock a target price of $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 19 ’25 when GEORGE V MIGAUSKY bought 28,188 shares for $14.58 per share.
Stout Jay S sold 1,925 shares of IMVT for $28,471 on Apr 23 ’25. The Chief Technology Officer now owns 209,243 shares after completing the transaction at $14.79 per share. On Apr 23 ’25, another insider, Geffner Michael, who serves as the Chief Medical Officer of the company, sold 2,349 shares for $14.79 each. As a result, the insider received 34,742 and left with 225,370 shares of the company.
Stock Price History:
Over the past 52 weeks, IMVT has reached a high of $34.47, while it has fallen to a 52-week low of $12.72. The 50-Day Moving Average of the stock is -8.94%, while the 200-Day Moving Average is calculated to be -39.13%.
Shares Statistics:
A total of 147.20M shares are outstanding, with a floating share count of 68.14M. Insiders hold about 59.89% of the company’s shares, while institutions hold 56.09% stake in the company.
Earnings Estimates
The market rating for Immunovant Inc (IMVT) is a result of the insights provided by 10.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.65 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.64 and -$3.51 for the fiscal current year, implying an average EPS of -$2.87. EPS for the following year is -$2.89, with 11.0 analysts recommending between -$2.45 and -$3.59.
